Get to know our amazingly versatile and unique RVF® technology
Our Products in Action
Multiplo Multiplex Tests
MedMira’s Multiplo multiplex tests include combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis.
Miriad Research Tools
Miriad includes toolkits to develop new diagnostic tests and commercialized combination tests.
About MedMira
MedMira is dedicated to improving human health by providing the best in rapid diagnostics. Our patented Rapid Vertical Flow Technology™ delivers fast, accurate results for a range of applications—helping care providers and their patients know more, instantly.
MedMira Strengthens and Expands Board
Halifax, Nova Scotia, 14 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the
appointment of Ms. Pascale Nini to the Board of Directors.
MedMira Receives Patent for its Unique Quantitative Diagnostic System
Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt
of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system.
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
Halifax, Nova Scotia, 27 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark.
May 20, 2022
VYRATM Product Line Update
Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRATM product line.
©2020 MedMira Inc. All Rights Reserved.